Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients with Chronic Heart Failure

Circulation

Volumn 109, Issue 10, 2004, Pages 1212-1214

  Lim, Melissa ^a   Honisett, Suzy ^b   Sparkes, Christopher D ^a   Komesaroff, Paul ^b   Kompa, Andrew ^a   Krum, Henry ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Endothelium; Heart failure; Ions; Peptides; Vasculature

Indexed keywords

UROTENSIN II;

ADULT; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART FAILURE; HUMAN; LASER DOPPLER FLOWMETRY; MALE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SKIN BLOOD FLOW;

ACETYLCHOLINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IONTOPHORESIS; LASER-DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; NITROPRUSSIDE; RECEPTORS, G-PROTEIN-COUPLED; SKIN; UROTENSINS; VASODILATOR AGENTS;

EID: 1642343080     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000121326.69153.98     Document Type: Article

References (16)

1. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282-286.
2. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol. 2002;135:25-27.
3. Hillier C, Berry C, Petrie MC, et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation. 2001;103:1378-1381.
4. Wilkinson IB, Affolter JT, de Haas SL, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res. 2002;53:341-347.
5. Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res. 2003;93:246-253.
6. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol. 2001;132:5-9.
7. Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359:1990-1997.
8. Richards AM, Nicholls MG, Lainchbury JG, et al. Plasma urotensin II in heart failure. Lancet. 2002;360:545-546.
9. Ng LL, Loke I, O'Brien RJ, et al. Plasma urotensin in human systolic heart failure. Circulation. 2002;106:2877-2880.
10. Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol. 2003;285:H1576-H1581.
11. Dschietzig T, Bartsch C, Pregla R, et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept. 2002;110:33-38.
12. Katz SD. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol. 1997;12:259-264.
13. Honisett SY, Pang B, Stojanovska L, et al. Progesterone does not influence vascular function in postmenopausal women. J Hypertens. 2003;21:1145-1149.
14. Douglas SA. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr Opin Pharmacol. 2003;3:159-167.
15. Krum H, Gilbert RE. Urotensin II: a new player in vascular and myocardial disease? Clin Sci (Lond). 2003;104:65-67.
16. Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol. 2001;280:H925-H928.